Switch theme
Sign up to access all valuation multiples
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
1998
32
LTM Revenue $48.4M
LTM EBITDA $12.6M
$221M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fennec Pharmaceuticals has a last 12-month revenue (LTM) of $48.4M and a last 12-month EBITDA of $12.6M.
In the most recent fiscal year, Fennec Pharmaceuticals achieved revenue of $34.3M and an EBITDA of $3.5M.
Fennec Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fennec Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $48.4M | XXX | $34.3M | XXX | XXX | XXX |
| Gross Profit | $45.4M | XXX | $32.0M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $12.6M | XXX | $3.5M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $4.1M | XXX | $1.9M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $1.9M | XXX | -$0.3M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fennec Pharmaceuticals's stock price is CAD 11 (or $8).
Fennec Pharmaceuticals has current market cap of CAD 311M (or $224M), and EV of CAD 306M (or $221M).
See Fennec Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $221M | $224M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fennec Pharmaceuticals has market cap of $224M and EV of $221M.
Fennec Pharmaceuticals's trades at 6.4x EV/Revenue multiple, and 63.8x EV/EBITDA.
Equity research analysts estimate Fennec Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fennec Pharmaceuticals has a P/E ratio of 119.0x.
See valuation multiples for Fennec Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $224M | XXX | $224M | XXX | XXX | XXX |
| EV (current) | $221M | XXX | $221M | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | 17.5x | XXX | 63.8x | XXX | XXX | XXX |
| EV/EBIT | 53.9x | XXX | 119.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 119.0x | XXX | -712.6x | XXX | XXX | XXX |
| EV/FCF | 9.7x | XXX | 11.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFennec Pharmaceuticals's last 12 month revenue growth is 18%
Fennec Pharmaceuticals's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.9M for the same period.
Fennec Pharmaceuticals's rule of 40 is -41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fennec Pharmaceuticals's rule of X is 71% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fennec Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 82% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -41% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 71% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 88% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fennec Pharmaceuticals acquired XXX companies to date.
Last acquisition by Fennec Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Fennec Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fennec Pharmaceuticals founded? | Fennec Pharmaceuticals was founded in 1998. |
| Where is Fennec Pharmaceuticals headquartered? | Fennec Pharmaceuticals is headquartered in Canada. |
| How many employees does Fennec Pharmaceuticals have? | As of today, Fennec Pharmaceuticals has 32 employees. |
| Who is the CEO of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's CEO is Mr. Jeffrey S. Hackman. |
| Is Fennec Pharmaceuticals publicy listed? | Yes, Fennec Pharmaceuticals is a public company listed on TSE. |
| What is the stock symbol of Fennec Pharmaceuticals? | Fennec Pharmaceuticals trades under FRX ticker. |
| When did Fennec Pharmaceuticals go public? | Fennec Pharmaceuticals went public in 2001. |
| Who are competitors of Fennec Pharmaceuticals? | Similar companies to Fennec Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's current market cap is $224M |
| What is the current revenue of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's last 12 months revenue is $48.4M. |
| What is the current revenue growth of Fennec Pharmaceuticals? | Fennec Pharmaceuticals revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Fennec Pharmaceuticals? | Current revenue multiple of Fennec Pharmaceuticals is 4.6x. |
| Is Fennec Pharmaceuticals profitable? | Yes, Fennec Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's last 12 months EBITDA is $12.6M. |
| What is Fennec Pharmaceuticals's EBITDA margin? | Fennec Pharmaceuticals's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Fennec Pharmaceuticals? | Current EBITDA multiple of Fennec Pharmaceuticals is 17.5x. |
| What is the current FCF of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's last 12 months FCF is $22.9M. |
| What is Fennec Pharmaceuticals's FCF margin? | Fennec Pharmaceuticals's last 12 months FCF margin is 47%. |
| What is the current EV/FCF multiple of Fennec Pharmaceuticals? | Current FCF multiple of Fennec Pharmaceuticals is 9.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
